Sabby Management’s Inovio Pharmaceuticals INO Stock Holding History

Sabby Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-11	Closed	-$114K	–	176
2020 Q4	$114K	Buy	+11	New	+$1.46K	0.02%	94
2020 Q3	–	Sell	-208	Closed	-$6.72M	–	143
2020 Q2	$6.72M	Buy	+208	New	+$33.4K	1.35%	14
2016 Q1	–	Sell	-333	Closed	-$2.68M	–	320
2015 Q4	$2.68M	Buy	333 +3	+0.9%	+$239	0.15%	103
2015 Q3	$2.29M	Buy	+330	New	+$28.8K	0.09%	141

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sabby Management's INO Position: Q1 2021 in Review

Sabby Management sold out of Inovio Pharmaceuticals (INO) in Q1 2021, closing a stake of 23,782 shares — an estimated $2.53M sold.

Sabby Management first reported a position in INO in Q2 2015 and held it in 6 quarters. The position peaked at $7.39M in Q2 2015. 218 funds tracked by Wall St. Rank hold INO as of Q1 2021.

Sabby Management reported no remaining Inovio Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Sabby Management sold 23,782 Inovio Pharmaceuticals shares in Q1 2021, an estimated $2.53M.
Sabby Management first reported a position in Inovio Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Sabby Management's Inovio Pharmaceuticals position peaked at $7.39M in Q2 2015.
218 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.